Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

Journal of the National Cancer Institute

Volumn 98, Issue 8, 2006, Pages 545-556

  Yaguchi, Shin Ichi ^a,b   Fukui, Yasuhisa ^c   Koshimizu, Ichiro ^b   Yoshimi, Hisashi ^b   Matsuno, Toshiyuki ^b   Gouda, Hiroaki ^d   Hirono, Shuichi ^d   Yamazaki, Kanami ^a   Yamori, Takao ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b ZENYAKU KOGYO CO LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; DOXORUBICIN; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; IRINOTECAN; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHORUS 32; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN; ZSTK 116; ZSTK 1178; ZSTK 474; ZSTK 781; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PIP3 APB; PIP3-APB; ZSTK474;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL LYSATE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TOXICITY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; CHROMATIN; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENETICS; METABOLISM; MOUSE STRAIN; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; CHROMONES; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MORPHOLINES; PHOSPHATIDYLINOSITOLS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 33646447708     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj133     Document Type: Article

References (54)

1. Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 1989;57:167-75.
2. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988;332:644-6.
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
4. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003;4:257-62.
5. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK. The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity. J Biol Chem 2000;275:6267-75.
6. Jimenez C, Jones DR, Rodriguez-Viciana P, Gonzalez-Garcia A, Leonardo E, Wennstrom S, et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 1998;17:743-53.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
8. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8.
9. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK-3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21: 99-102.
10. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/ PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8.
11. Kobayashi M, Nagata S, Iwasaki T, Yanagihara K, Saitoh I, Karouji Y, et al. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 1999;96:4874-9.
12. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancer. Nat Genet 1997;15:356-62.
13. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, et al. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 2003;278:23630-8.
14. Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K, et al. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res 2003;31:670-82.
15. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem 1994;269:3563-7.
16. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54:2419-23.
17. Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, et al. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org Biomol Chem 2004;2:1911-20.
18. Woscholski R, Kodaki T, McKinnon M, Waterfield MD, Parker PJ. A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase. FEBS Lett 1994;342:109-14.
19. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
20. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
21. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004;32:393-6.
22. Yaguchi S, Izumisawa Y, Sato M, Nakagane T, Koshimizu I, Sakita K, et al. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull 1997;20:698-700.
23. Matsuno T, Karo M, Sasahara H, Watanabe T, Inaba M, Takahashi M, et al. Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives. Chem Pharm Bull (Tokyo) 2000;48:1778-81.
24. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002;62: 1139-47.
25. Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 2003; 52 Suppl 1:S74-9.
26. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999;59:4042-9.
27. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
28. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
29. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
31. Boyd MR. Status of the National Cancer Institute preclinical antitumor drug discovery screen: Implications for selection of new agents for clinical trial. Vol 3. Philadelphia (PA): Lippincott; 1989.
32. Fukui Y, Kornbluth S, Jong SM, Wang LH, Hanafusa H. Phosphatidylinositol kinase type I activity associates with various oncogene products. Oncogene Res 1989;4:283-92.
33. Gray A, Olsson H, Batty IH, Priganica L, Peter Downes C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003;313:234-45.
34. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261:470-89.
35. Tsujishita H, Hirono S. CAMDAS: An automated conformational analysis system using molecular dynamics. Conformational Analyzer with Molecular Dynamics And Sampling. J Comput Aided Mol Des 1997;11:305-15.
36. Radwan AA, Gouda H, Yamaotsu N, Torigoe H, Hirono S. Rational procedure for 3D-QSAR analysis using TRNOE experiments and computational methods: application to thermolysin inhibitors. Drug Des Discov 2001;17:265-81.
37. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982;161:269-88.
38. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267: 727-48.
39. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997;11:425-45.
40. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. J Med Chem 1999;42:791-804.
41. Katsuki M, Chuang VT, Nishi K, Kawahara K, Nakayama H, Yamaotsu N, et al. Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein. J Biol Chem 2005;280:1384-91.
42. Kimura K, Hattori S, Kabuyama Y, Shizawa Y, Takayanagi J, Nakamura S, et al. Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1994;269:18961-7.
43. Plank J, Rychlo A. [A method for quick decalcification.]. Zentralbl Allg Pathol 1952;89:252-4.
44. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphonositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19.
45. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol 1997;4:796-801.
46. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-6.
47. Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 1999;59:4004-11.
48. Holleran JL, Egorin MJ, Zuhowski EG, Parise RA, Musser SM, Pan SS. Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 2003;323:19-25.
49. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
50. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003;63:3585-92.
51. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002;8:1957-63.
52. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Them 2002;1:989-97.
53. Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol 1999;44:491-7.
54. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72.